Key Takeaways

  • RetinaLyze System has received EU MDR Class 2a certification covering four retinal and glaucoma screening modules

  • Validation demonstrated sensitivities of 90.67% for diabetic retinopathy, 84.51% for AMD, and 89.63% for glaucoma screening

RetinaLyze System A/S has received Class 2a medical device certification under the European Union Medical Device Regulation (MDR) for its clinical decision support software used to identify potential signs of diabetic retinopathy, age-related macular degeneration (AMD), and glaucoma in fundus images.

The certification, issued by TÜV SÜD Product Service GmbH, covers four software modules: RetinaLyze DR Screening, RetinaLyze AMD Screening, RetinaLyze Glaucoma Screening, and RetinaLyze Advanced Glaucoma.

The transition from Class 1 to Class 2a introduces independent assessment of the manufacturer's quality management system and technical documentation, along with ongoing surveillance. The MDR certificate is valid through October 15, 2031.

RetinaLyze System analyzes fundus images for retinal and optic nerve head abnormalities, including small dark and white lesions and variations in optic nerve head coloration. Findings are displayed as color-coded overlays to assist eye care professionals in identifying potential disease. The software does not provide diagnoses, and its findings must be interpreted alongside original images, patient history, and other clinical information.

According to validation data reported in the product's instructions for use, the software demonstrated the following performance against specialist grading:

The diabetic retinopathy module demonstrated a positive predictive value of 8.93% and a negative predictive value of 99.80% in the validation population, reflecting the low prevalence of disease among those evaluated.

“Moving from Class 1 to Class 2a means an independent Notified Body now assesses our quality system and technical documentation,” said Teddy Birch Petersen, CEO of RetinaLyze System A/S.

The certification does not change the software's existing functionality. RetinaLyze reports that more than 7 million analyses have been performed using its platform since 2013, with availability in more than 20 countries.